Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients

• Published in: BioMed research international Vol. 2018; no. 2018; pp. 1 - 8
• Main Authors: Chen, Jin-Bor, Hsu, Chung-Yuan, Chiu, Wen-Chan, Su, Yu-Jih, Ng, Hwee-Yeong
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc
• Subjects: Adult; Apheresis; Autoimmune diseases; Biomedical research; Canada; Demography; Exchanging; Female; Guillain-Barre syndrome; Hepatitis; Homeostasis; Hospital Mortality; Humans; Immunoglobulins; Laboratories; Lupus; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - mortality; Lupus Erythematosus, Systemic - therapy; Male; Mortality; Multivariate analysis; Patient outcomes; Patients; Peripheral neuropathy; Plasma Exchange - adverse effects; Plasma Exchange - mortality; Plasmapheresis; Plasmapheresis - adverse effects; Plasmapheresis - mortality; Rheumatic diseases; Rheumatology; Subgroups; Survival Analysis; Systemic lupus erythematosus; Canada; Japan
• ISSN: 2314-6133; 2314-6141; 2314-6141
• DOI: 10.1155/2018/9707932

Background. Apheresis treatment includes plasmapheresis (PP) and plasma exchange (PE), and these terms are commonly used interchangeably. Nevertheless, the two procedures are carried out differently. The aims of this study were to investigate the mortality rate of patients who underwent therapeutic apheresis and compare the mortality rate between PP and PE. Methods. We conducted a medical chart review retrospective study. All identified subjects (n=436) were over 20 years old with at least one ICD-9-CM intervention code plasmapheresis or plasma exchange and at least one diagnosis code with rheumatic disease. All of them were hospitalized to Chang Gung Memorial Hospital between 1st of January, 2000, and 31st of December, 2014. Results. 436 nonoverlapping patients had never received PE and/or PP before 1 Jan, 2000. Among all the patients, 350 received PE, 63 received PP, and 23 received both therapies. Female patients accounted for 85.09% of patients. The overall mortality rate was 4.65% in the PE subgroup, 4.76% with combination therapy, and 13.46% in the PP subgroup. There were 374 patients diagnosed as SLE, which is the majority of overall patients who received PE and/or PE. In multivariate analysis, PE was the sole independent factor predictor of survival in SLE subgroup patients (p=0.02, exp(B)=0.314, 95% CI 0.12–0.81). Conclusions. We showed that both PP and PE were used in treating a variety of autoimmune disorders. Plasmapheresis was preferentially carried out in patients with peripheral neuropathy. In 374 lupus patients treated with either PE or PP, PE is superior to PP in reducing in-hospital mortality.